» Articles » PMID: 22608558

Fibroblast Activation Protein-α: a Key Modulator of the Microenvironment in Multiple Pathologies

Overview
Publisher Elsevier
Date 2012 May 22
PMID 22608558
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Fibroblast activation protein-α (FAP) is a serine protease that can provide target specificity to therapeutic agents because in adults its expression is restricted to pathologic sites, including cancer, fibrosis, arthritis, wounding, or inflammation. It is not expressed in most normal tissues. The majority of FAP is expressed by activated fibroblasts responding to the pathologic situations. FAP is typically found as a type II transmembrane protein physically attached to cells and with the bulk of the protein, including the catalytic domain, exposed to the extracellular space and accessible to small molecules. In this chapter, we review the structure, substrate specificities, signaling functions, and current design of FAP inhibitors. Evidence indicating the presence of FAP in multiple cancers, arthritis, fibrosis, keloids, and other pathologies is described and indicates possible roles for FAP in facilitating cell invasion and growth. Separate sections are devoted to the role of FAP in coordinating the stromal response to cancer, including a role in angiogenesis and a potential role in modulation of the antitumor immune response. Finally studies attempting to demonstrate the clinical potential of FAP are discussed, as well as some novel applications employing FAP in therapy or diagnosis. Throughout this review, effort is made to highlight areas where information is lacking and to highlight important questions that require further investigation.

Citing Articles

Current status of FAP-directed cancer theranostics: a bibliometric analysis.

Ruan D, Wu S, Lin X, Zhao L, Cai J, Xu W Biophys Rep. 2025; 10(6):388-402.

PMID: 39758423 PMC: 11693499. DOI: 10.52601/bpr.2024.240022.


Ga-FAPI-46 PET/CT in the evaluation of gliomas: comparison with F-FDG PET/CT and contrast-enhanced MRI.

Ruan D, Sun J, Han C, Cai J, Yu L, Zhao L Theranostics. 2024; 14(18):6935-6946.

PMID: 39629119 PMC: 11610146. DOI: 10.7150/thno.103399.


Comparison Length of Linker in Compound for Nuclear Medicine Targeting Fibroblast Activation Protein as Molecular Target.

Hisada K, Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Saito A, Watabe T Int J Mol Sci. 2024; 25(22).

PMID: 39596363 PMC: 11594969. DOI: 10.3390/ijms252212296.


Integrated omics profiling reveals systemic dysregulation and potential biomarkers in the blood of patients with neuromyelitis optica spectrum disorders.

Xie Z, Zhou Q, Hu J, He L, Meng H, Liu X J Transl Med. 2024; 22(1):989.

PMID: 39487546 PMC: 11529322. DOI: 10.1186/s12967-024-05801-8.


[Ga]Ga-DOTAGA-Glu(FAPi) Shows Enhanced Tumor Uptake and Theranostic Potential in Preclinical PET Imaging.

van Krimpen Mortensen J, Mattiussi S, Hvass L, Lund E, Shalgunov V, Roesch F Diagnostics (Basel). 2024; 14(18).

PMID: 39335703 PMC: 11431137. DOI: 10.3390/diagnostics14182024.